James  Clavijo net worth and biography

James Clavijo Biography and Net Worth

CFO of Longeveron
James Clavijo joined Longeveron in 2019. He has over 25 years of experience in executive, finance and accounting activities, including experience as a Chief Financial Officer for several pharmaceutical, healthcare, medical device and manufacturing companies. Mr. Clavijo’s experience has included building, leading and advising companies with strategic plans for pharmaceutical commercialization and manufacturing, negotiating licensing and drug development agreements, as well as advising companies with complex restructurings, mergers and acquisitions, capital market transactions, and system implementations. During 2018, Mr. Clavijo served as the Chief Financial Officer for Aeterna Zentaris (NASDAQ: AEZS). Prior to this, Mr. Clavijo served for two years as the Chief Financial Officer for Tri-source Pharma, a pharmaceutical company focused on procuring pharmaceutical products facing supply issues and supplying pharmaceutical products to veterinary markets. Since 2009, Mr. Clavijo, has also served as founder and principal of Barcelona Capital Partners, a consulting firm that provided Chief Financial Officer services, that includes the preparation of regulatory filings with the Securities and Exchange Commission. Previously, Mr. Clavijo served for five years as the Chief Accounting Officer at Soligenix (NASDAQ: SNGX), a public biopharmaceutical company. In addition, Mr. Clavijo worked for Deloitte & Touche and was an Officer in the U.S. Army, serving for 13 years in active and reserve duty. Mr. Clavijo was licensed as a CPA in Florida from 2000-2011. He was licensed in Florida as a real estate/business agent since 2013-2021. Mr. Clavijo received a BA in Chemistry (PreMed) from the University of Florida, a BA in Accounting from the University of Nebraska, and a Masters in Accounting from Florida International University.

What is James Clavijo's net worth?

The estimated net worth of James Clavijo is at least $135,820.54 as of June 27th, 2023. Mr. Clavijo owns 62,303 shares of Longeveron stock worth more than $135,821 as of September 24th. This net worth estimate does not reflect any other assets that Mr. Clavijo may own. Learn More about James Clavijo's net worth.

How do I contact James Clavijo?

The corporate mailing address for Mr. Clavijo and other Longeveron executives is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. Longeveron can also be reached via phone at 305-302-7158 and via email at [email protected]. Learn More on James Clavijo's contact information.

Has James Clavijo been buying or selling shares of Longeveron?

James Clavijo has not been actively trading shares of Longeveron during the last ninety days. Most recently, James Clavijo sold 5,000 shares of the business's stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $3.51, for a transaction totalling $17,550.00. Following the completion of the sale, the chief financial officer now directly owns 47,303 shares of the company's stock, valued at $166,033.53. Learn More on James Clavijo's trading history.

Who are Longeveron's active insiders?

Longeveron's insider roster includes James Clavijo (CFO), Geoff Green (CEO), Joshua Hare (Insider), Paul Lehr (General Counsel), and Rock Soffer (Director). Learn More on Longeveron's active insiders.

Are insiders buying or selling shares of Longeveron?

During the last year, insiders at the sold shares 5 times. They sold a total of 153,532 shares worth more than $568,641.36. The most recent insider tranaction occured on June, 29th when CFO James Clavijo sold 5,000 shares worth more than $17,550.00. Insiders at Longeveron own 75.2% of the company. Learn More about insider trades at Longeveron.

Information on this page was last updated on 6/29/2023.

James Clavijo Insider Trading History at Longeveron

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/29/2023Sell5,000$3.51$17,550.0047,303View SEC Filing Icon  
6/27/2023Sell8,532$3.48$29,691.3662,303View SEC Filing Icon  
6/3/2022Sell36,955$8.26$305,248.3079,619View SEC Filing Icon  
10/7/2021Buy5,000$3.34$16,700.00View SEC Filing Icon  
See Full Table

James Clavijo Buying and Selling Activity at Longeveron

This chart shows James Clavijo's buying and selling at Longeveron by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Longeveron Company Overview

Longeveron logo
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $2.18
Low: $2.12
High: $2.26

50 Day Range

MA: $2.85
Low: $2.15
High: $3.53

2 Week Range

Now: $2.18
Low: $2.12
High: $4.81


37,589 shs

Average Volume

321,916 shs

Market Capitalization

$46.15 million

P/E Ratio


Dividend Yield